A derivative of the murine ovarian ID8 model has previously been targeted with neoantigen vaccines that increased the proportion of activated CD4+ and CD8+ T cells but did not result in T cell–mediated tumor control due to insufficient MHC-presented neoantigen epitopes.37 This evidence concerns the gene CD8A and neoplasm.